311 related articles for article (PubMed ID: 32561830)
1. The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides.
Meyrath M; Szpakowska M; Zeiner J; Massotte L; Merz MP; Benkel T; Simon K; Ohnmacht J; Turner JD; Krüger R; Seutin V; Ollert M; Kostenis E; Chevigné A
Nat Commun; 2020 Jun; 11(1):3033. PubMed ID: 32561830
[TBL] [Abstract][Full Text] [Related]
2. Human herpesvirus 8-encoded chemokine vCCL2/vMIP-II is an agonist of the atypical chemokine receptor ACKR3/CXCR7.
Szpakowska M; Dupuis N; Baragli A; Counson M; Hanson J; Piette J; Chevigné A
Biochem Pharmacol; 2016 Aug; 114():14-21. PubMed ID: 27238288
[TBL] [Abstract][Full Text] [Related]
3. Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists.
Szpakowska M; Meyrath M; Reynders N; Counson M; Hanson J; Steyaert J; Chevigné A
Biochem Pharmacol; 2018 Jul; 153():299-309. PubMed ID: 29530506
[TBL] [Abstract][Full Text] [Related]
4. Emerging Roles of the Atypical Chemokine Receptor 3 (ACKR3) in Cardiovascular Diseases.
Duval V; Alayrac P; Silvestre JS; Levoye A
Front Endocrinol (Lausanne); 2022; 13():906586. PubMed ID: 35846294
[TBL] [Abstract][Full Text] [Related]
5. Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3.
Szpakowska M; Nevins AM; Meyrath M; Rhainds D; D'huys T; Guité-Vinet F; Dupuis N; Gauthier PA; Counson M; Kleist A; St-Onge G; Hanson J; Schols D; Volkman BF; Heveker N; Chevigné A
Br J Pharmacol; 2018 May; 175(9):1419-1438. PubMed ID: 29272550
[TBL] [Abstract][Full Text] [Related]
6. Mutational Analysis of Atypical Chemokine Receptor 3 (ACKR3/CXCR7) Interaction with Its Chemokine Ligands CXCL11 and CXCL12.
Benredjem B; Girard M; Rhainds D; St-Onge G; Heveker N
J Biol Chem; 2017 Jan; 292(1):31-42. PubMed ID: 27875312
[TBL] [Abstract][Full Text] [Related]
7. Ligand-specific conformational transitions and intracellular transport are required for atypical chemokine receptor 3-mediated chemokine scavenging.
Montpas N; St-Onge G; Nama N; Rhainds D; Benredjem B; Girard M; Hickson G; Pons V; Heveker N
J Biol Chem; 2018 Jan; 293(3):893-905. PubMed ID: 29180449
[TBL] [Abstract][Full Text] [Related]
8. The natural analgesic conolidine targets the newly identified opioid scavenger ACKR3/CXCR7.
Szpakowska M; Decker AM; Meyrath M; Palmer CB; Blough BE; Namjoshi OA; Chevigné A
Signal Transduct Target Ther; 2021 Jun; 6(1):209. PubMed ID: 34075018
[No Abstract] [Full Text] [Related]
9. Structure-Activity Relationship Study of Cyclic Pentapeptide Ligands for Atypical Chemokine Receptor 3 (ACKR3).
Sekiguchi H; Kuroyanagi T; Rhainds D; Kobayashi K; Kobayashi Y; Ohno H; Heveker N; Akaji K; Fujii N; Oishi S
J Med Chem; 2018 Apr; 61(8):3745-3751. PubMed ID: 29608300
[TBL] [Abstract][Full Text] [Related]
10. Functions of the CXCL12 Receptor ACKR3/CXCR7-What Has Been Perceived and What Has Been Overlooked.
Koch C; Engele J
Mol Pharmacol; 2020 Nov; 98(5):577-585. PubMed ID: 32883765
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Atypical Chemokine Receptor ACKR3/CXCR7: Phase 1 - Phage Display Peptide Identification and Characterization.
Vestal RD; LaJeunesse DR; Taylor EW
Curr Top Med Chem; 2016; 16(13):1427-40. PubMed ID: 26369825
[TBL] [Abstract][Full Text] [Related]
12. α
Albee LJ; Eby JM; Tripathi A; LaPorte HM; Gao X; Volkman BF; Gaponenko V; Majetschak M
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862946
[TBL] [Abstract][Full Text] [Related]
13. ACKR3 Regulation of Neuronal Migration Requires ACKR3 Phosphorylation, but Not β-Arrestin.
Saaber F; Schütz D; Miess E; Abe P; Desikan S; Ashok Kumar P; Balk S; Huang K; Beaulieu JM; Schulz S; Stumm R
Cell Rep; 2019 Feb; 26(6):1473-1488.e9. PubMed ID: 30726732
[TBL] [Abstract][Full Text] [Related]
14. Atypical opioid receptors: unconventional biology and therapeutic opportunities.
Palmer CB; Meyrath M; Canals M; Kostenis E; Chevigné A; Szpakowska M
Pharmacol Ther; 2022 May; 233():108014. PubMed ID: 34624426
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of CXCL12 binding to atypical chemokine receptor 3 reveal a role for the receptor N terminus in chemokine binding.
Gustavsson M; Dyer DP; Zhao C; Handel TM
Sci Signal; 2019 Sep; 12(598):. PubMed ID: 31506383
[TBL] [Abstract][Full Text] [Related]
16. The relevance of the chemokine receptor ACKR3/CXCR7 on CXCL12-mediated effects in cancers with a focus on virus-related cancers.
Freitas C; Desnoyer A; Meuris F; Bachelerie F; Balabanian K; Machelon V
Cytokine Growth Factor Rev; 2014 Jun; 25(3):307-16. PubMed ID: 24853339
[TBL] [Abstract][Full Text] [Related]
17. Emerging roles of atypical chemokine receptor 3 (ACKR3) in normal development and physiology.
Quinn KE; Mackie DI; Caron KM
Cytokine; 2018 Sep; 109():17-23. PubMed ID: 29903572
[TBL] [Abstract][Full Text] [Related]
18. Discovery and Development of First-in-Class ACKR3/CXCR7 Superagonists for Platelet Degranulation Modulation.
Bayrak A; Mohr F; Kolb K; Szpakowska M; Shevchenko E; Dicenta V; Rohlfing AK; Kudolo M; Pantsar T; Günther M; Kaczor AA; Poso A; Chevigné A; Pillaiyar T; Gawaz M; Laufer SA
J Med Chem; 2022 Oct; 65(19):13365-13384. PubMed ID: 36150079
[TBL] [Abstract][Full Text] [Related]
19. Atypical Chemokine Receptor 3 (ACKR3): A Comprehensive Overview of its Expression and Potential Roles in the Immune System.
Koenen J; Bachelerie F; Balabanian K; Schlecht-Louf G; Gallego C
Mol Pharmacol; 2019 Dec; 96(6):809-818. PubMed ID: 31040166
[TBL] [Abstract][Full Text] [Related]
20. Ackr3-Venus knock-in mouse lights up brain vasculature.
Ehrlich AT; Semache M; Couvineau P; Wojcik S; Kobayashi H; Thelen M; Gross F; Hogue M; Le Gouill C; Darcq E; Bouvier M; Kieffer BL
Mol Brain; 2021 Sep; 14(1):151. PubMed ID: 34583741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
